Tamper resistant dosage forms
The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.
1. A solid oral extended release pharmaceutical dosage form, comprising a shaped, convection heated, and cooled extended release matrix, said matrix comprising at least one polyethylene oxide (PEO) having, based on rheological measurements, an approximate molecular weight of at least 800,000, and at least one opioid analgesic, wherein (a) the shaped matrix is convection heated to an elevated temperature that is at least the softening temperature of said PEO for a time period of at least about 1 minute and thereafter cooled; and (b) a plurality of convection heated particles of PEO adhere to or fuse with each other within the matrix.
2. The dosage form of claim 1 , wherein said time period is at least about 15 minutes.
3. The dosage form of claim 1 , wherein said elevated temperature is at least about 55° C.
4. The dosage form of claim 1 , wherein said elevated temperature is at least about 62° C.
5. The dosage form of claim 1 , wherein the total PEO content of the shaped matrix is at least about 15% (by weight) of said matrix.
6. The dosage form of claim 5 , wherein said time period is at least about 5 minutes and said elevated temperature is at least about 55° C.
7. The dosage form of claim 6 , wherein said PEO has, based on rheological measurements, an approximate molecular weight of at least 1,000,000.
8. The dosage form of claim 6 , wherein said PEO has, based on rheological measurements, an approximate molecular weight of at least 4,000,000.
9. The dosage form of claim 6 , wherein said elevated temperature is at least about 60° C.
10. The dosage form of claim 6 , wherein said elevated temperature is at least about 68° C.
11. The dosage form of claim 6 , wherein said opioid analgesic is oxycodone or a pharmaceutically acceptable salt thereof.
12. The dosage form of claim 6 , wherein said active agent is hydrocodone or a pharmaceutically acceptable salt thereof.
13. The dosage form of claim 1 , wherein the total PEO content of the shaped matrix is at least about 30% (by weight) of said matrix.
14. The dosage form of claim 1 , wherein the total PEO content of the shaped matrix is at least about 50% (by weight) of said matrix.
15. The dosage form of claim 1 , wherein the extended release matrix is shaped by direct compression to form a tablet.
16. The dosage form of claim 1 , wherein said cooling is at a temperature of below 50° C.
17. The dosage form of claim 1 , wherein the extended release matrix is shaped to form a tablet and heated in a coating pan; said time period is at least about 5 minutes; and said elevated temperature is at least about 60° C.
18. The dosage form of claim 17 , wherein the opioid analgesic is oxycodone or a pharmaceutically acceptable salt thereof.
19. The dosage form of claim 17 , wherein the opioid analgesic is hydrocodone or a pharmaceutically acceptable salt thereof.
20. The dosage form of claim 1 , wherein said time period is at least about 5 minutes and said elevated temperature is at least about 55° C.
21. A solid oral extended release tablet, comprising a shaped, convection heated, and cooled extended release matrix, said matrix comprising at least one polyethylene oxide (PEO) having, based on rheological measurements, an approximate molecular weight of at least 800,000, and at least one opioid analgesic, wherein (a) the shaped matrix is convection heated to an elevated temperature of at least 55° C. for a time period of at least about 15 minutes and thereafter cooled at a temperature below 50° C.; and (b) a plurality of convection heated particles of PEO adhere to or fuse with each other within the matrix.
22. The tablet of claim 21 , wherein the total PEO content of the matrix is at least about 20% (by weight) of the composition.
23. The tablet of claim 21 , wherein the total PEO content of the matrix is at least about 50% (by weight) of the composition.
24. The tablet of claim 21 , wherein said elevated temperature is at least about 62° C.
25. The tablet of claim 21 , wherein said opioid analgesic is oxycodone or a pharmaceutically acceptable salt thereof, in a dosage amount selected from 10, 15, 20, 30, 40, 60 and 80 mg.
26. The tablet of claim 21 , wherein said opioid analgesic is hydrocodone or a pharmaceutically acceptable salt thereof, in a dosage amount selected from 20, 30, 40, 60, 80, 100, and 120 mg.
27. The tablet of claim 21 , wherein said PEO has, based on rheological measurements, an approximate molecular weight of at least 1,000,000.
28. The tablet of claim 21 , wherein said PEO has, based on rheological measurements, an approximate molecular weight of at least 4,000,000.
29. The tablet of claim 21 , wherein the dosage form further comprises at least one of a cellulosic additive, magnesium stearate, talc, silica, fumed silica, colloidal silica dioxide, calcium stearate, carnauba wax, stearic acid, stearyl alcohol, mineral oil, paraffin, glycerin, propylene glycol, polyethylene glycol, lactose, povidone, triacetin, and copolymers comprising methyl methacrylate.
30. The tablet of claim 29 , wherein the cellulosic additive is microcrystalline or hydroxypropylated.